Business
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), will hold a virtual R&D symposium on December 7, 2021, from 10:00am – 12:00pm ET. The event will feature a presentation on dementia with Lewy bodies (DLB) pathology, treatment and patient burden by leaders in the DLB community. In addition, members of the Cognition management team will review the Company’s plans to advance a small molecule sigma-2 (σ-2) modulator for the treatment of DLB. Speakers will include: James E. Galvin, MD, MPH: Professor of Neurology and Director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine; Chief of Cognitive Disorder Services for Palm Beach, FloridaAngela Taylor: Senior Director of Research and Advocacy for the Lewy Body Dementia Association (LBDA)Lisa Ricciardi: President & CEO, Cognition TherapeuticsAnthony Caggiano, MD, PhD: Chief Medical Officer and Head of R&D, Cognition TherapeuticsMary Hamby, PhD: VP Research, Cognition Therapeutics Registration for the event is open on the events page of the Company’s website. A live webcast of the discussion and an archived recording will also be available on the events webpage. About Dementia with Lewy BodiesAn estimated 1.4 million Americans are living with DLB, a progressive disease that accounts for approximately 5-10% of all dementia cases. DLB, has overlapping pathology and symptomology of Parkinson’s and Alzheimer’s diseases, making it challenging to diagnose. DLB is caused by a build-up of a protein, α-synuclein, which forms deposits, called Lewy bodies, in the brain. Oligomers of α-synuclein are highly toxic and bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and loss. Patients with DLB often experience cognitive, physical, sleep and behavioral symptoms, including hallucinations, delusions and mood changes. There are currently no disease-modifying treatments approved for DLB patients. About Cognition TherapeuticsCognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discover...